Landmark Results From Depression Efficacy Study To Be Presented By CNS Response At U.S. Psychiatric And Mental Health Congress

CNS Response, Inc. (OTCBB: CNSO) announced that the company will present top-line results from its multi-site clinical trial next week at the U.S. Psychiatric and Mental Health Congress. "Referenced-EEG (rEEG®) Efficacy Compared to Star*D for Patients with Depression Treatment Failure: First Look at Final Results," will be presented by Charles DeBattista, M.D. on Monday, November 2nd, at 3:45 to 6:45 p.m. The conference is being held at the Mandalay Bay South Convention Center in Las Vegas, NV.


Dr. DeBattista is Professor of Psychiatry and Behavioral Health Sciences at Stanford University School of Medicine, and Director of the Depression and Psychopharmacology Clinic at Stanford Medical Center. Dr. DeBattista specializes in psychiatry with special expertise in clinical depression, disorders of excessive somnolence, electroconvulsive therapy, and fatigue.


CNS Response will be conducting an investor conference call and webcast discussing the top-line results on Tuesday, November 3rd, at 8:00 a.m. PST, 11:00 a.m. EST. Details of the conference call will be announced shortly.


Source

CNS Response